ES2162825T3 - Derivados de piperazina. - Google Patents

Derivados de piperazina.

Info

Publication number
ES2162825T3
ES2162825T3 ES94100709T ES94100709T ES2162825T3 ES 2162825 T3 ES2162825 T3 ES 2162825T3 ES 94100709 T ES94100709 T ES 94100709T ES 94100709 T ES94100709 T ES 94100709T ES 2162825 T3 ES2162825 T3 ES 2162825T3
Authority
ES
Spain
Prior art keywords
piperazine derivatives
fibrinogen
treatment
apoplejia
infarto
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94100709T
Other languages
English (en)
Inventor
Joachim Prof Dr Gante
Peter Dr Raddatz
Horst Dr Juraszyk
Sabine Dr Bernotat-Danielowski
Guido Dr Melzer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Application granted granted Critical
Publication of ES2162825T3 publication Critical patent/ES2162825T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Hydrogenated Pyridines (AREA)
  • Indole Compounds (AREA)

Abstract

NUEVO DERIVADO PIPERAZINA DE LA FORMULA I DONDE R1, R2, Y, Z, M, N Y R TIENEN EL SIGNIFICADO DADO EN LA REIVINDICACION DE PATENTE 1. INHIBEN LA FORMACION DE FIBRINOGENO EN EL RECEPTOR DE FIBRINOGENO Y PUEDEN SER UTILIZADOS PARA EL TRATAMIENTO DE TROMBOSIS, APOPLEJIA, INFARTO, INFECCIONES, ARTERIOSCLEROSIS ASI COMO EN EL TRATAMIENTO DE TUMORES.
ES94100709T 1993-01-29 1994-01-19 Derivados de piperazina. Expired - Lifetime ES2162825T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4302485A DE4302485A1 (de) 1993-01-29 1993-01-29 Piperazinderivate

Publications (1)

Publication Number Publication Date
ES2162825T3 true ES2162825T3 (es) 2002-01-16

Family

ID=6479203

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94100709T Expired - Lifetime ES2162825T3 (es) 1993-01-29 1994-01-19 Derivados de piperazina.

Country Status (21)

Country Link
US (1) US5908843A (es)
EP (1) EP0608759B1 (es)
JP (1) JPH06271549A (es)
KR (1) KR100312539B1 (es)
CN (1) CN1056141C (es)
AT (1) ATE204570T1 (es)
AU (1) AU670649B2 (es)
CA (1) CA2114361A1 (es)
CZ (1) CZ288122B6 (es)
DE (2) DE4302485A1 (es)
DK (1) DK0608759T3 (es)
ES (1) ES2162825T3 (es)
GR (1) GR3036838T3 (es)
HU (1) HU222013B1 (es)
NO (1) NO312550B1 (es)
PL (1) PL172716B1 (es)
PT (1) PT608759E (es)
RU (1) RU2154639C2 (es)
SK (1) SK281842B6 (es)
UA (1) UA34429C2 (es)
ZA (1) ZA94615B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL115420A0 (en) 1994-09-26 1995-12-31 Zeneca Ltd Aminoheterocyclic derivatives
WO1997028128A1 (en) 1996-02-02 1997-08-07 Zeneca Limited Heterocyclic compounds useful as pharmaceutical agents
GB9602166D0 (en) * 1996-02-02 1996-04-03 Zeneca Ltd Aminoheterocyclic derivatives
GB9602294D0 (en) * 1996-02-05 1996-04-03 Zeneca Ltd Heterocyclic compounds
EP0917462B1 (en) * 1996-07-25 2006-09-13 Biogen Idec MA Inc. Cell adhesion inhibitors
ATE230399T1 (de) * 1996-08-14 2003-01-15 Astrazeneca Ab Substituierte pyrimidinderivate und ihre pharmazeutische anwendung
UA56197C2 (uk) 1996-11-08 2003-05-15 Зенека Лімітед Гетероциклічні похідні
AU5999698A (en) 1997-02-13 1998-09-08 Zeneca Limited Heterocyclic compounds useful as oxido-squalene cyclase inhibitors
WO1998035959A1 (en) 1997-02-13 1998-08-20 Zeneca Limited Heterocyclic compounds useful as oxido-squalene cyclase inhibitors
GB9715895D0 (en) 1997-07-29 1997-10-01 Zeneca Ltd Heterocyclic compounds
DE19743435A1 (de) * 1997-10-01 1999-04-08 Merck Patent Gmbh Benzamidinderivate
FR2781221B1 (fr) * 1998-07-17 2000-10-13 Lafon Labor Piperazinones substituees en alpha
FR2781220B1 (fr) * 1998-07-17 2000-10-13 Lafon Labor Piperazinones substituees en beta
DE19835950A1 (de) * 1998-08-08 2000-02-10 Merck Patent Gmbh Piperazinonderivate
GB9902989D0 (en) 1999-02-11 1999-03-31 Zeneca Ltd Heterocyclic derivatives
CN1253442C (zh) * 1999-07-26 2006-04-26 参天制药株式会社 新型噻嗪和吡嗪衍生物
CN1703395A (zh) * 2002-08-09 2005-11-30 特兰斯泰克制药公司 芳基和杂芳基化合物以及调节凝血的方法
WO2004108076A2 (en) * 2003-06-02 2004-12-16 Samaritan Pharmaceuticals, Inc. Anti-hiv benzamide compounds
US20060194814A1 (en) * 2003-06-02 2006-08-31 Vassilios Papadopoulos Benzamide compounds
US7208601B2 (en) * 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
WO2005014532A1 (en) * 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions and methods of use
TW200738701A (en) 2005-07-26 2007-10-16 Du Pont Fungicidal carboxamides
EP1909797A4 (en) * 2005-08-02 2013-02-27 Neurogen Corp DIPIPERAZINYL KETONE AND RELATED ANALOG
CN113473987A (zh) 2018-12-19 2021-10-01 细胞基因公司 被取代的3-((3-氨基苯基)氨基)哌啶-2,6-二酮化合物、其组合物和使用其的治疗方法
CA3124130A1 (en) 2018-12-19 2020-06-25 Celgene Corporation Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3711335A1 (de) * 1987-04-03 1988-10-20 Merck Patent Gmbh Aminosaeurederivate
US5053393A (en) * 1988-07-20 1991-10-01 Monsanto Company Novel platelet-aggregation inhibitor
US5084466A (en) * 1989-01-31 1992-01-28 Hoffmann-La Roche Inc. Novel carboxamide pyridine compounds which have useful pharmaceutical utility
DE4007869A1 (de) * 1990-03-13 1991-09-19 Merck Patent Gmbh Aminosaeurederivate
IL99537A (en) * 1990-09-27 1995-11-27 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical preparations containing them
AU646966B2 (en) * 1991-08-23 1994-03-10 Takeda Chemical Industries Ltd. 2-piperazinone compounds, their production and use
JP3719612B2 (ja) * 1993-06-14 2005-11-24 塩野義製薬株式会社 ヘテロ環を含有する尿素誘導体

Also Published As

Publication number Publication date
KR940018372A (ko) 1994-08-16
DE4302485A1 (de) 1994-08-04
NO312550B1 (no) 2002-05-27
JPH06271549A (ja) 1994-09-27
CZ288122B6 (cs) 2001-04-11
CN1099759A (zh) 1995-03-08
CZ16394A3 (en) 1994-08-17
AU670649B2 (en) 1996-07-25
PT608759E (pt) 2002-02-28
DE59409833D1 (de) 2001-09-27
PL302069A1 (en) 1994-08-08
GR3036838T3 (en) 2002-01-31
PL172716B1 (pl) 1997-11-28
EP0608759A3 (de) 1994-10-05
SK6894A3 (en) 1994-08-10
CN1056141C (zh) 2000-09-06
SK281842B6 (sk) 2001-08-06
ATE204570T1 (de) 2001-09-15
NO940308L (no) 1994-08-01
HU222013B1 (hu) 2003-03-28
NO940308D0 (no) 1994-01-28
HUT70042A (en) 1995-09-28
ZA94615B (en) 1994-09-13
HU9400249D0 (en) 1994-05-30
DK0608759T3 (da) 2001-12-03
UA34429C2 (uk) 2001-03-15
EP0608759A2 (de) 1994-08-03
RU2154639C2 (ru) 2000-08-20
AU5470294A (en) 1994-08-04
KR100312539B1 (ko) 2002-02-19
CA2114361A1 (en) 1994-07-30
US5908843A (en) 1999-06-01
EP0608759B1 (de) 2001-08-22

Similar Documents

Publication Publication Date Title
ES2162825T3 (es) Derivados de piperazina.
GEP20074251B (en) N-oxycarbonyl substituted 5'- deoxy-5-fluorocytidines
FI953748A0 (fi) Yhdisteitä, joilla on sekä voimakas kalsium antagonisti- että antioksidanttiaktiivisuus sekä niiden käyttö solua suojaavina aineina
DK0842934T3 (da) 5-HT1F agonister
ATE181735T1 (de) Substituierte 1-phenyl-oxazolidin-2-on derivate, deren herstellung und deren verwendung als adhäsionsrezeptor-antagonisten
MX9702382A (es) Nuevos derivados de pirimidona con actividad antifungica.
ATE413388T1 (de) Muskarin antagonisten
ES2184077T3 (es) Nuevas fenantridinas sustituidas en la posicion 6.
ATE416157T1 (de) Inhibitoren von integrin alpha-v-beta-6
ATE332903T1 (de) Kondensierte pyridoindolderivate
DE69838662D1 (de) Morphinanderivate und ihre medizinische Anwendung
NO20001483L (no) Nye NPY-agonister
EP0261912A3 (en) 2- or 3- Aryl substituted imidazo [1,2-a] pyridines
DE69914357D1 (de) Pyridin-4-yl oder pyrimidin-4-yl substituierte pyrazine
PT1086096E (pt) Benzamidas com substituintes etra-hidrofuraniloxi como inibidores da fosfodiesterase 4
ATE391715T1 (de) Heterozyklische mutilinester und deren verwendung als bakterizide
DE60112960D1 (de) Kondensierte pyridoindolderivate
TR200100133T2 (tr) FKBP İnhibitörleri
ATE330958T1 (de) Pyrazino 1'2':1,6öpyrido 3,4-böindolderivate
MXPA03003971A (es) Derivados de indol como inhibidores de pde5.
DE69814563D1 (de) Pyrrolo-(3,2-b)pyridine und ihre Verwendung als 5-HT1F Agonisten
TR199901416T2 (xx) Heterosiklik karbonikasit t�revleri.
UY26498A1 (es) Pirroles sustituidos
ATE491457T1 (de) Kombinationstherapie gegen tumoren mit substituierten acryloyl-distamycin-derivaten, taxanen und/oder antimetaboliten
DE60227113D1 (de) Kondensierte camptothecine als antitumormittel

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 608759

Country of ref document: ES